IOL Chemicals and Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	756	552	+37.1%
EBITDA	103	62.1	+66.5%
EBITDA margin	13.7%	11.3%	+2.4 pts
Profit before tax	86.7	45.5	+90.5%
Net profit	64.4	33.9	+89.8%
EPS	₹2.20	₹1.16	+89.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	756	619	580	568	552	528	523	526	502	504	520	545	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.2	1.8	5.3	6.9	7.4	4.5	4.1	6.4	7.4	7.5	8.4	7.1
	764	621	586	574	559	532	527	532	510	511	529	552
	507	402	357	367	377	348	336	352	323	349	358	351
	0.8	3.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−29.5	−33.2	25.6	1.5	−12.3	−1.8	18.1	3.9	13.4	−26.8	−2.1	2.5
	71.2	70.3	56.9	63.4	57.7	52.4	52.4	58.7	53.1	49.7	48.3	49.0
	3.6	3.2	3.6	3.5	4.2	4.0	4.5	4.1	2.2	3.4	4.3	4.4
	21.3	20.3	20.2	20.0	19.8	18.6	18.7	17.9	16.8	16.4	16.3	15.7
	104	84.4	83.7	78.9	67.7	66.9	70.0	69.8	61.9	82.2	71.8	78.6
	678	550	547	534	514	488	500	506	470	474	497	501
	103	92.5	57.3	57.1	62.1	62.8	46.9	41.6	51.1	49.5	44.4	64.2
	82.2	72.2	37.1	37.1	42.4	44.2	28.2	23.6	34.3	33.1	28.0	48.5
Profit
	86.7	70.8	38.8	40.5	45.5	44.7	27.8	25.9	39.5	37.2	32.1	51.2
	0.0	0.0	−11.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	86.7	70.8	27.6	40.5	45.5	44.7	27.8	25.9	39.5	37.2	32.1	51.2
	21.7	15.1	6.0	9.0	10.5	7.1	4.3	4.6	8.8	5.0	6.3	11.1
	0.6	2.5	1.0	1.6	1.1	6.2	2.9	2.2	0.8	4.6	2.7	2.2
	22.3	17.7	7.0	10.5	11.6	13.3	7.3	6.8	9.6	9.6	9.0	13.3
	64.4	53.2	20.6	30.0	33.9	31.4	20.5	19.2	30.0	27.6	23.1	37.9
	64.4	53.2	20.6	30.0	33.9	31.4	20.5	19.2	30.0	27.6	23.1	37.9
	−1.0	2.7	0.1	0.4	−0.6	0.0	−0.1	0.1	−1.4	0.3	0.1	−0.5
	63.4	55.9	20.7	30.4	33.3	31.4	20.4	19.2	28.5	27.9	23.2	37.4
Per share
	₹2.20	₹1.81	₹0.70	₹1.02	₹1.16	₹1.07	₹3.50	₹3.26	₹5.11	₹4.71	₹3.93	₹6.45
	₹2.20	₹1.81	₹0.70	₹1.02	₹1.16	₹1.07	₹3.50	₹3.26	₹5.11	₹4.71	₹3.93	₹6.45
Other comprehensive income — detail
	−1.0	2.7	0.1	0.4	−0.6	0.0	—	—	—	—	—	—
	−1.4	2.7	1.1	0.7	−1.9	0.9	−0.1	−0.0	−1.8	0.4	0.1	−0.6
	−0.3	0.7	0.3	0.2	−0.5	0.2	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.5	0.1	0.0	−0.2
	−0.0	1.0	−0.9	−0.2	1.0	−0.9	−0.1	0.2	−0.1	—	0.0	−0.0
	−0.0	0.2	−0.2	−0.1	0.3	−0.2	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	0.0	−0.0	−0.0	0.0	0.0
Per share — as-filed variants
	₹2.20	₹1.81	₹0.70	₹1.02	₹1.16	₹1.07	₹3.50	₹3.26	₹5.11	₹4.71	₹3.93	₹6.45
	₹2.20	₹1.81	₹0.70	₹1.02	₹1.16	₹1.07	₹3.50	₹3.26	₹5.11	₹4.71	₹3.93	₹6.45
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	278	247	198	199	187	182	169	170	166	181	164	192
	36.8%	39.9%	34.1%	35.1%	34.0%	34.5%	32.3%	32.4%	33.0%	36.0%	31.6%	35.2%
Adjusted (ex-exceptional items) — derived
	86.7	70.8	38.8	40.5	45.5	44.7	27.8	25.9	39.5	37.2	32.1	51.2
	0.0	0.0	−11.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	64.4	53.2	29.0	30.0	33.9	31.4	20.5	19.2	30.0	27.6	23.1	37.9
	₹2.20	₹1.81	₹0.98	₹1.02	₹1.16	₹1.07	₹3.50	₹3.26	₹5.11	₹4.71	₹3.93	₹6.45

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IOLCP₹180.62

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMOREPENLAB FDC INNOVACAP ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹5,302 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	545.3	520.4	503.9	502.4	525.8	523.3	527.8	551.7	567.5	580.4	619.5	756.3
Other Income	7.1	8.4	7.5	7.4	6.4	4.1	4.5	7.4	6.9	5.3	1.8	8.2
Total Income	552.4	528.8	511.4	509.8	532.2	527.4	532.3	559.1	574.4	585.7	621.3	764.4
Expenses
+ Cost of Materials Consumed	351.0	358.1	349.3	323.0	351.8	336.0	347.6	376.6	366.7	356.7	401.7	506.8
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.8	0.8
+ Changes in Inventories	2.5	-2.1	-26.8	13.4	3.9	18.1	-1.8	-12.3	1.5	25.6	-33.2	-29.5
+ Employee Benefit Expense	49.0	48.3	49.7	53.1	58.7	52.4	52.4	57.7	63.4	56.9	70.3	71.2
+ Finance Costs	4.4	4.3	3.4	2.2	4.1	4.5	4.0	4.2	3.5	3.6	3.2	3.6
+ Depreciation & Amortisation	15.7	16.3	16.4	16.8	17.9	18.7	18.6	19.8	20.0	20.2	20.3	21.3
+ Other Expenses	78.6	71.8	82.2	61.9	69.8	70.0	66.9	67.7	78.9	83.7	84.4	103.6
Total Expenses	501.2	496.7	474.2	470.2	506.2	499.6	487.6	513.6	533.9	546.9	550.5	677.8
EBITDA	64.2	44.4	49.5	51.1	41.6	46.9	62.8	62.1	57.1	57.3	92.5	103.5
EBIT	48.5	28.0	33.1	34.3	23.6	28.2	44.2	42.4	37.1	37.1	72.2	82.2
Profit
PBT before Exceptional Items	51.2	32.1	37.2	39.5	25.9	27.8	44.7	45.5	40.5	38.8	70.8	86.7
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.2	0.0	0.0
Pretax Income	51.2	32.1	37.2	39.5	25.9	27.8	44.7	45.5	40.5	27.6	70.8	86.7
+ Current Tax	11.1	6.3	5.0	8.8	4.6	4.3	7.1	10.5	9.0	6.0	15.1	21.7
+ Deferred Tax	2.2	2.7	4.6	0.8	2.2	2.9	6.2	1.1	1.6	1.0	2.5	0.6
Tax Expense	13.3	9.0	9.6	9.6	6.8	7.3	13.3	11.6	10.5	7.0	17.7	22.3
Net Income	37.9	23.1	27.6	30.0	19.2	20.5	31.4	33.9	30.0	20.6	53.2	64.4
+ Net Income — Continuing Ops	37.9	23.1	27.6	30.0	19.2	20.5	31.4	33.9	30.0	20.6	53.2	64.4
+ Other Comprehensive Income	-0.5	0.1	0.3	-1.4	0.1	-0.1	0.0	-0.6	0.4	0.1	2.7	-1.0
Total Comprehensive Income	37.4	23.2	27.9	28.5	19.2	20.4	31.4	33.3	30.4	20.7	55.9	63.4
Per Share
Basic EPS	6.45	3.93	4.71	5.11	3.26	3.50	1.07	1.16	1.02	0.70	1.81	2.20
Diluted EPS	6.45	3.93	4.71	5.11	3.26	3.50	1.07	1.16	1.02	0.70	1.81	2.20
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.0	-0.6	0.4	0.1	2.7	-1.0
+ Items NOT to be Reclassified to P&L	-0.6	0.1	0.4	-1.8	-0.0	-0.1	0.9	-1.9	0.7	1.1	2.7	-1.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.2	-0.5	0.2	0.3	0.7	-0.3
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	0.0	0.1	-0.5	-0.0	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-0.0	0.0	—	-0.1	0.2	-0.1	-0.9	1.0	-0.2	-0.9	1.0	-0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-0.2	0.3	-0.1	-0.2	0.2	-0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	-0.0	-0.0	0.0	-0.0	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.45	3.93	4.71	5.11	3.26	3.50	1.07	1.16	1.02	0.70	1.81	2.20
Diluted EPS — Continuing Operations	6.45	3.93	4.71	5.11	3.26	3.50	1.07	1.16	1.02	0.70	1.81	2.20
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	191.8	164.4	181.4	166.0	170.1	169.3	182.0	187.5	199.4	198.0	247.2	278.3
Gross Margin %	35.17	31.60	36.00	33.04	32.36	32.34	34.48	33.98	35.13	34.11	39.90	36.80
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	51.2	32.1	37.2	39.5	25.9	27.8	44.7	45.5	40.5	38.8	70.8	86.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.2	0.0	0.0
Net Income Adj (tax-effected)	37.9	23.1	27.6	30.0	19.2	20.5	31.4	33.9	30.0	29.0	53.2	64.4
EPS Adj	6.45	3.93	4.71	5.11	3.26	3.50	1.07	1.16	1.02	0.98	1.81	2.20
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	58.7	58.7	58.7	58.7	58.7	58.7	58.7	58.7	58.7	58.7	58.7	58.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

IOL Chemicals and Pharmaceuticals Q2 FY27 results date

IOL Chemicals and Pharmaceuticals (NSE: IOLCP) will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, according to the board-meeting notice it filed on 23 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹64.4 crore, up 89.8% from ₹33.9 crore in Q1 FY26 and up 21.1% from ₹53.2 crore in Q4 FY26. Revenue from operations was ₹756 crore, up 37.1% year on year and up 22.1% from the previous quarter.

Board-meeting notice filed: 23 October 2026
Q2 FY26 results (a year earlier): 11 November 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 30 October 2026Friday · notice filed 23 Oct
Q1 FY27 net profit: ₹64.4 Cr+89.8% vs Q1 FY26+21.1% vs Q4 FY26
Q1 FY27 revenue: ₹756 Cr+37.1% vs Q1 FY26+22.1% vs Q4 FY26
Q1 FY27 operating margin: 10.9%+3.2 pts vs Q1 FY26−0.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹30 CrRevenue ₹568 Cr
Q1 FY27 EPS (basic): ₹2.20

Questions

When will IOL Chemicals and Pharmaceuticals announce its Q2 FY27 results?

On 30 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 23 October 2026). Last year it reported Q2 FY26 on 11 November 2025.

What was IOL Chemicals and Pharmaceuticals' net profit in FY26?

Consolidated net profit was ₹138 crore in FY26 (April 2025–March 2026), up 36.2% from ₹101 crore in FY25. It was ₹134 crore in FY24 and ₹139 crore in FY23: down 1.1% over three years, an average fall of 0.4% a year.

What was IOL Chemicals and Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹2,319 crore in FY26 (April 2025–March 2026), up 11.5% from ₹2,079 crore in FY25. It was ₹2,133 crore in FY24 and ₹2,217 crore in FY23: up 4.6% over three years, 1.5% a year on average.

What will IOL Chemicals and Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹30 crore and revenue from operations ₹568 crore. The latest quarter, Q1 FY27, had a net profit of ₹64.4 crore and revenue of ₹756 crore.

What were IOL Chemicals and Pharmaceuticals' Q1 FY27 results?

Consolidated net profit was ₹64.4 crore, up 89.8% from ₹33.9 crore in Q1 FY26 and up 21.1% from ₹53.2 crore in Q4 FY26. Revenue from operations was ₹756 crore, up 37.1% year on year and up 22.1% from the previous quarter.

How has IOL Chemicals and Pharmaceuticals' profit changed over the last four quarters?

Net profit by quarter: ₹30 crore in Q2 FY26, ₹20.6 crore in Q3 FY26, ₹53.2 crore in Q4 FY26 and ₹64.4 crore in Q1 FY27. That is ₹168 crore over the four quarters, up 60.1% from ₹105 crore in the four quarters before. Revenue from operations: ₹568 crore, ₹580 crore, ₹619 crore and ₹756 crore.

Where do these IOL Chemicals and Pharmaceuticals figures come from?

From IOL Chemicals and Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.